At a glance

ClinicalIndex Comparison Record

N/ACompleted· 8 enrolled

Drug / intervention

HD PET/CTother

Likely dose

Not stated in record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01110174

NCT01110174N/ACompleted

Compare CT.gov

Assessing Response to Neoadjuvant Chemotherapy With Dedicated Breast High Definition PET/CT, Serum Glycomic Markers and Tissue Muc-1 Isoforms

University of California, Davis·interventional·Posted Apr 26, 2010·Updated Nov 21, 2019

In Brief

A clinical study evaluating HD PET/CT for Breast Cancer. Completed, enrolled 8 participants across 1 site.

Detailed Summary

A pilot study of adult (≥ 18 years) women with stage II-III breast cancer who will receive preoperative chemotherapy prior to mastectomy. Patients will have real-time serum glycan profiling, expression of tissue MUC 1 oncoprotein isoforms to predict neoadjuvant chemotherapy response and additional mammography and HD PET/CT examinations to assess response. The investigators hypothesize that a functional tumor assessment utilizing high-definition positron emission tomography/computed tomography (HD PET/CT), real-time serum glycan profiling, and expression of tissue MUC 1 oncoprotein isoforms will predict neoadjuvant chemotherapy response in breast cancer patients.

Study Details

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsBreast Cancer

CountriesUnited States

Collaborators--

Timeline

N/ACompletedFinished

20102011201220132014201520162017201820192020202120222023202420252026

Enrollment StartMar 2010

First PostedApr 2010

Primary CompletionMar 2016

TodayJul 2026

First PostedApr 26, 2010

Enrollment StartMar 1, 2010

Primary CompletionMar 1, 2016

TodayJul 2, 2026

Enrollment to primary: 6 yearsPosted 16.2 years ago

Interventions

HD PET/CTother

imaging